Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daunorubicin Citrate

FDA-approved product (injectable, liposomal, injection), marketed as Daunoxome, Cerubidine, Daunorubicin Hydrochloride.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Daunorubicin Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myeloid leukemia
  • Lymphoid leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 2 lab records
Open Daunorubicin Citrate in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daunorubicin Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

    NCT00003035 · start 1997-03

    Registered record
    Registry ID
    NCT00003035
    Conditions
    Breast Cancer
    Interventions
    filgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate; surgical procedure; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-03
    Completion
    2001-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionfilgrastim; doxorubicin hydrochloride; paclitaxel; tamoxifen citrate +2 more
    PhasePhase 2
    Registry statusCompleted

  • High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

    NCT00002945 · start 1996-12

    Registered record
    Registry ID
    NCT00002945
    Conditions
    Leukemia
    Interventions
    aldesleukin; filgrastim; cyclophosphamide; cytarabine; etoposide; idarubicin; melphalan; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-12
    Completion
    2011-08
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionaldesleukin; filgrastim; cyclophosphamide; cytarabine +5 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

    NCT00002919 · start 1996-11

    Registered record
    Registry ID
    NCT00002919
    Conditions
    Bladder Cancer
    Interventions
    filgrastim; cisplatin; doxorubicin hydrochloride; methotrexate; vinblastine sulfate; conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-11
    Completion
    2003-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    Interventionfilgrastim; cisplatin; doxorubicin hydrochloride; methotrexate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Children With Lymphoma

    NCT00002590 · start 1994-07

    Registered record
    Registry ID
    NCT00002590
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1994-07
    Completion
    2007-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

    NCT00002494 · start 1992-05

    Registered record
    Registry ID
    NCT00002494
    Conditions
    Leukemia; Lymphoma
    Interventions
    cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; mesna; methotrexate; prednisone; therapeutic hydrocortisone; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1992-05
    Completion
    2006-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventioncyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride +10 more
    PhasePhase 2
    Registry statusCompleted